by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : July 2009
Perficio Product Development announces exciting new hosting service Perficio Product Development offers unparalleled experience and sophisticated business systems to assist with all of the functions required to successfully realise your medical device concept. Perficio Product Development also offers a whole Quality Management System and operating processes within a hosted environment. What does this mean for your company? Simply log on to our web server and you are within your own fully compliant, completely secure development environment, complete with QMS and operating processes (e.g. risk management, requirements management, document management, issues management). We are also delighted to announce that Dr John McCarthy has joined our team as Principal Scientist. John has extensive experience in commercialising biotechnology products, has successfully managed in-house product development activities and has established effective product development, manufacturing and quality system (ISO13485) environments. Steve Marshall AIPM, Chief Executive Officer Sean Williams BE (Elec) (Hons) Dip Eng Practice, Principal Systems Engineer Dr John McCarthy BSc (Hons) MSc PhD Principal Scientist Ben Johnston BE BMedSc (Hons), Mechatronics Engineering Pierre Vancaillie BE BmedSc (Hons), Biomechanical Engineering Leanne Maslen MM, Management Systems and Administration Perficio Product Development, Suite 304, Studio 54 Foveaux Street, Surry Hills, NSW 2010 t +61 2 9211 0399 f +61 2 9211 0424 e firstname.lastname@example.org www.perficio.com.au members. Many thanks to those members who were active and vocal throughout the campaign, as working together was, and will continue, to be vital. The package signalled that the Government truly views technology and innovation as the foundation stones of the future that will lead us to economic recovery and job growth. As if demonstrating its incredible value on cue, Australian biotechnology has been at the forefront of the recent swine flu outbreak, with its significant role in the development of Relenza, one of the only two anti-viral medicines shown to be affective against the flu H1/N1 strain. Relenza was developed by Australian company Biota and is now manufactured and sold by GlaxoSmith Kline, providing a successful example of much-needed world-class biotechnology. Pioneering work to develop Relenza was carried out in Australia by three scientists and their teams – Graeme Laver, Peter Colman and Mark von Itzstein – and manufacturing continues here today. With our established position and reputation, and Government support now pledged, the scene is set for Australian science and innovation to firmly cement its position as a global leader in R&D. To do so, industry and government must now convert these budget policies into reality so that Australian biotechnology companies have the ability to successfully commercialise their science on our shores. While this budget package is a welcome win, there is much work to be done. AusBiotech will continue to work with the Government to ensure that the implementation of budget measures achieve the desired outcomes and we will work with the Opposition to ensure that the future of our industry is secure through tough times via bi-partisan support. As a membership organisation, we will continue to represent your interests – and conversely rely on your renewed membership for 2009/10 to continue our work. * Estimate provided by Deloitte, based on data provided by Biotechnologynews.net and includes R&D spend of 103 companies in the 2008 calendar year. Volume 19 • Number 2 • July 2009 Australasian BioTechnology 5